Background: Few effective treatments are available for patients with Waldenstrom's macroglobulinemia that is resistant to standard therapies. We assessed the activity of 2-chlorodeoxyadenosine (2CdA) in patients with resistant macroglobulinemia in order to identify those most likely to benefit.
Introduction
The primary therapy of Waldenstrom's macroglobulinemia has usually consisted of chemotherapy with alkylating agents and steroids which has induced responses in about one half of the patients [1] [2] [3] [4] . With resistance or relapse, 2-chlorodeoxyadenosine (2CdA) has been effective in approximately 40% of patients [5] . Previous studies included small series followed for a short duration, precluding a systematic analysis of prognostic factors. In this follow up study of 46 patients with previously treated macroglobulinemia, we identified the patients most likely to benefit.
Patients and methods
Between August 1990 and March 1994, 46 previously treated patients with Waldenstrom's macroglobulinemia received 2 CdA (R. W. Johnson Pharmaceutical Company, Orthobiotech Inc., Raritan, New Jersey) after informed consent was obtained according to institutional guidelines. Patient characteristics are shown in Table  1 . The median age was 60 years (range 34 to 81 years) and 21 were male. The primary reasons for treatment were progressive anemia (19 patients), lymphadenopathy or organomegaly (10 patients), hyperviscosity syndrome (10 patients), cold-agglutinin disease (2 patients), cryoglobulinemia (1 patient), peripheral neuropathy (2 patients) and renal impairment due to Bence Jones proteinuria or amyloidosis (2 patients).
The macroglobulinemia was relapsing from an unmaintained remission in 9 patients (relapse off treatment), had never responded to previous treatments in 20 patients (primary resistance) and was relapsing despite salvage therapy in 17 patients (refractory relapse). Chemotherapy regimens prior to 2CdA treatment are shown in Table 2 . The median interval between first treatment and 2CdA therapy was 9 months for patients with primary refractory disease and 59 months for patients with refractory relapse. Thirteen patients had been treated previously with a median of 4 courses of fludarabine (range 2 to 9 courses) which was given at a dose of 20-30 mg/m 2 IV per day for 5 days every 4 weeks. All patients underwent baseline evaluations that included blood cell counts, hepatic and renal function tests, bone marrow aspirate and biopsy, quantitation of CD4+ and CD8+ blood lymphocytes, serum protein electrophoresis, and quantitation of serum immunoglobulins and b 2 -microglobulin. Chest-x-rays and computed tomography of the abdomen and pelvis were also performed. While on treatment, patients were followed with weekly blood counts; serum electrophoretic studies were repeated monthly and complete restaging was done after completion of therapy.
The study was approved by our Institution's Ethic-Committee and adhered to the declaration of Helsinki; all patients were required to provide written informed consent 2-Chlorodeoxyadenosine was administered to outpatients at a dose of 0.1 mg/kg body weight per day for a 7-day continuous infusion using a portable pump through a central venous catheter. Two courses of 2CdA were given 4 weeks apart and responding patients were followed without further therapy until disease relapse.
Partial response was defined as a sustained decrease by at least 50% of serum monoclonal IgM concentration for at least 2 months, accompanied by more than a 50% reduction of tumor infiltrate at all involved sites. Complete response was defined as the disappearance of monoclonal protein by serum immunofixation and resolution of all other evidence of disease. Relapse was defined as an increase of serum monoclonal protein by at least 25% above the lowest value, or reappearance of lymphadenopathy or anemia. Multiple parameters were assessed for their correlation with response, progression free and overall survival times.
Comparisons using chi-square analysis were performed on all categorical variables. Progression-free survival and overall survival were calculated using the method of Kaplan and Meier and differences compared by a Wilcoxon test [6] . A P value of <0.05 was considered to indicate statistical significance.
Results

Response
Twenty of 46 patients responded (43%; 95% CI 29%-60%) including one patient with a complete response. The median time to a 50% reduction of monoclonal IgM was 1.5 months (range 0.2 to 3.0 months). Even after cessation of therapy the level of abnormal protein continued to fall in all responding patients along with disease reduction at involved sites. Thus, lymphadenopathy was reduced by more than 50% in all responding patients and disappeared in 4 patients; bone marrow lymphocytosis was reduced by at least 50% in all patients with more than 25% infiltration. Among responding patients, hemoglobin values of less than 100 g/L increased by at least 20 g/L in 12 of 15 patients, and thrombocytopenia resolved in all affected patients.
The occurrence of response was more likely during certain phases of disease. Patients with disease relapsing off therapy and with primary resistance of less than 1 year had significantly higher response rates than patients treated during refractory relapse or with primary resistance of more than 1 year (Table 3 ). Responses to 2CdA were observed in 3 of 4 patients who had responded previously to fludarabine and were relapsing off therapy; only 1 of 9 patients with disease resistant to fludarabine responded to 2CdA. The patient's age or gender, the presence of lymphadenopathy or splenomegaly, the pretreatment hemoglobin, the degrees of blood or marrow lymphocytosis, or the serum level of abnormal protein or b 2 -microglobulin and the pretreatment number of CD4+ or CD8+ blood lymphocytes, were not associated with response.
Survival and remission
The median survival of all patients was 28 months. Among multiple clinical and laboratory features, only the disease status prior to 2CdA appeared to correlate with survival. The median survival was 13 months for patients treated during refractory relapse, 28 months for those relapsing off therapy and has not been reached for patients with primary resistant macroglobulinemia (Fig. 1) . All deaths were due to progressive macroglobulinemia with the exception of one patient who died in remission of squamous cell carcinoma of the anus.
The median progression free survival of all responding patients was 12 months and no clinical or laboratory parameters appeared to be predictive (Fig. 1) . Among patients with recurrent disease after follow up on no maintenance treatment, 6 were retreated with 2CdA and 4 responded for a duration of 2+, 3+, 4 and 6+ months. 
Toxicity
The degree of myelosuppression was moderate and reversible, the median lowest neutrophil count being 1.2 x 10 9 /L (range 0.1 to 5.0 x 10 9 /L) and the median lowest platelet count being 110 x 10 9 /L (range 8 to 250 x 10 9 /L). The second course of treatment was administered without delay after 4 weeks to 34 patients; in 5 patients, the second course was delayed 1-3 weeks and was omitted in 7 patients because of persistent thrombocytopenia (3 patients) or progressive macroglobulinemia (4 patients).
One pancytopenic patient before 2CdA treatment died on day 70 of aspergillus pneumonia; four patients developed neutropenic fever that responded to broad spectrum antibiotics, one patient developed reversible listeria sepsis, two a non-neutropenic bronchitis, and 4 patients a dermatomal herpes zoster. Furthermore, one patient died of nocardia asteroides pneumonia 6 months after retreatment with 2CdA given for relapsing disease. A marked decrease in the number of lymphocytes expressing CD4 surface antigen ('helper 5 phenotype) occurred in all patients (before treatment: 448 x 10 3 /L, 2 months after treatment: 125 x 10 3 /L; p < 0.01) with a less pronounced decrease in lymphocytes expressing the CD8 surface antigen ('suppressor phenotype') (before treatment: 337 x 10 3 /L, 2 months after treatment: 225 x 10 3 /L; p -0.14). Extramedullary organ toxicity was tolerable; 2 patients developed mild stomatitis, nausea or vomiting of moderate degree was noted in 3 patients and transient elevation of liver function tests was noted in 1 patient. There was no alopecia, abnormalities of renal function tests or fever during the administration of 2CdA.
Discussion
The primary therapy of patients with Waldenstrom's macroglobulinemia usually consists of a combination of an alkylating agent and a glucocorticoid which has induced responses in about one-half of the patients. While the median survival has been 5 years, patients who failed to respond lived a median of 2 years [1, 5] . Few reports are available on the treatment of patients who developed primary or secondary resistance to initial therapies. There have been limited trials with doxorubicin, high dose steroids, interferon-alpha or interferon gamma with occasional benefits reported [7] [8] [9] [10] . Fludarabine induced responses in one-third of patients who were resistant to prior therapies [11] and we observed a similar frequency of benefit in comparable patients with 2CdA. 2-Chlorodeoxyadenosine has also been effective for a variety of low-grade lymphoid neoplasms resistant to standard regimens such as chronic lymphocytic leukemia, hairy cell leukemia, and low grade B and T-cell lymphomas [12] [13] [14] [15] .
2-Chlorodeoxyadenosine is an adenosine deaminase-resistant purine analogue that is phosphorylated by deoxycitidine kinase and accumulates as chlorodeoxyadenosine triphosphate (Chlorod ATP) in cells rich in deoxycytidine kinase [16] . The ratio of deoxycytidine kinase activity to cytoplasmic 5'-nucleotidase expression correlates with subsequent sensitivity to 2CdA in patients with chronic lymphocytic leukemia [17] . Measurement of these parameters may help identify those patients with lymphoid neoplasms who are most likely to respond to 2CdA.
While 2CdA was usually well tolerated, marked and sustained CD4+ lymphocytopenia was noted along with several cases of opportunistic infection. Such occurrences have been reported previously and require a high index of suspicion for the early institution of effective therapy [18] . Our study also showed that a limited trial of 2 courses induced durable unmaintained remissions of many months duration. This indicates that repeated courses of 2CdA, which is likely to increase the degree and duration of immunosuppression, are not necessary. Furthermore, disease relapsing after prior responses to either alkylating agents or a nucleoside analogue was usually recontrolled after retreatment with 2CdA. Thus, tumor clones with preserved sensitivity to a nucleoside analogue remained dominant in most patients for a long duration. These observations justify long-term follow-up without treatment in responding patients with macroglobulinemia, as reported recently for responding patients with chronic lymphocytic leukemia [19] .
2-Chlorodeoxyadenosine was also active against primary resistant disease especially when treated early. The much lower response rate among patients with a longer duration of primary resistance or during refractory relapse may be due to the evolution, over time, of subclones that had developed resistance to multiple therapies. Prior resistance to fludarabine was also asso-dated with cross resistance to 2CdA as observed by others who used this sequence of agents for chronic lymphocytic leukemia [20] . Thus, patient groups unlikely to respond to 2CdA are candidates for new agents or for more intensive chemotherapy, such as with myeloablative treatments, in a manner found useful for selected patients with chronic lymphocytic leukemia and multiple myeloma [21, 22] .
